← Back to Search

Other

ESK-001 Dose Level 1 for Plaque Psoriasis

Phase 2

Waitlist Available

Research Sponsored by Alumis Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 weeks

Summary

This trial tests ESK-001, a new medication, on patients with moderate to severe plaque psoriasis. It aims to see if ESK-001 can help reduce inflammation and slow down skin cell growth. The study lasts for several months.

Eligible Conditions

Plaque Psoriasis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo

Secondary study objectives

To Assess the Response Rate in Static Physician's Global Assessment (sPGA) Score

To Assess the Safety and Tolerability of ESK-001 Dose in Moderate to Severe Psoriasis Patients

To Characterize the Pharmacokinetics (PK) of ESK-001

Side effects data

From 2023 Phase 2 trial • 228 Patients • NCT05600036

Nasopharyngitis

Headache

Upper respiratory tract infection

Cough

Acne

Pyrexia

Dermatitis acneiform

COVID-19

100%

80%

60%

40%

20%

Study treatment Arm

ESK-001 40mg BID

ESK-001 40mg QD

ESK-001 20mg BID

ESK-001 10mg QD

ESK-001 20mg QD

Placebo

Trial Design

6Treatment groups

Experimental Treatment

Placebo Group

Group I: ESK-001 Dose Level 5Experimental Treatment1 Intervention